What Is Saxenda Approved For? Label Indications, Per the Research

The short answer

Saxenda is a prescription medicine whose active ingredient is liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Its approved indication is narrow and specific: chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity. The US Food and Drug Administration approved Saxenda for adults in December 2014, the European Commission followed in March 2015, and in December 2020 the FDA extended the indication to adolescents aged 12 to 17 years with obesity. Any other application of liraglutide — in other age groups, for other conditions, or for metabolic goals outside weight management — sits outside the approved label and is described in the literature as off-label or investigational.

This page is for educational purposes only and is not medical advice; consult a licensed physician about whether any approved medicine is appropriate, and do not use this summary as a substitute for the current prescribing information in your country.

What the approved indication actually says

The weight-management indication is written around two eligibility thresholds that are standard across obesity pharmacotherapy. Reviews of weight-loss pharmacotherapy described the conventional candidate population for GLP-1-based obesity medicines as adults with a body mass index of 30 kg/m² or above, or 27 kg/m² or above in the presence of at least one weight-related condition such as hypertension, dyslipidaemia or type 2 diabetes (PMID 39277293). The Lancet review of obesity management placed pharmacotherapy in the same framework, as an addition to — not a replacement for — dietary and activity changes (PMID 26868660).

Two details are frequently confused and worth stating plainly:

• Saxenda is not the diabetes product. Liraglutide is marketed in two separate products at different strengths; the type 2 diabetes indication belongs to the other liraglutide product, not to Saxenda. Reviews of GLP-1 receptor agonists in type 2 diabetes described liraglutide's glucose-lowering role under that separate brand and indication (PMID 33068776).
• The indication is for chronic management. The label frames weight management as an ongoing treatment context rather than a short course, which matches how long-term reviews of anti-obesity treatment have discussed weight regain after discontinuation (PMID 33410104).

Approved indications and dates at a glance

Generic liraglutide injection products have also received regulatory approval in the United States; a generic carries the same approved indication as the reference product it copies, so a generic of the weight-management product is approved for weight management and a generic of the diabetes product is approved for diabetes.

Where the molecule came from

Liraglutide was engineered from the native GLP-1 sequence by adding a fatty-acid side chain that binds albumin and slows clearance, a design history described in detail in a review of the discovery and development of liraglutide and semaglutide (PMID 31031702). That same acylation strategy, pushed further, produced the once-weekly analogue semaglutide, whose medicinal-chemistry discovery programme was reported separately (PMID 26308095). The practical consequence is that liraglutide's pharmacokinetics support once-daily subcutaneous administration, which is the schedule used in the trials underpinning its weight-management approval (PMID 35015037).

Mechanistically, researchers have continued to map how the molecule reaches its central targets. A mouse study reported that tanycytes — specialised cells lining the third ventricle — controlled hypothalamic uptake of liraglutide and that this transport step was required for its anti-obesity actions (PMID 35716660). That work is mechanistic and preclinical; it explains the approved indication rather than extending it.

Trial evidence behind the weight-management indication

The approval rested on a programme of randomised trials in adults with obesity or overweight, and reviews have since placed liraglutide within the broader class. A 2024 review of weight-loss pharmacotherapy summarised GLP-1 receptor agonists as the most effective approved injectable options for obesity at the time of writing, with liraglutide among the agents discussed (PMID 39277293). A review of long-term anti-obesity treatment reported that durability of effect and tolerability over extended periods remained central questions for all approved agents in this class (PMID 33410104).

Head-to-head comparison: STEP 8

The clearest direct comparison of the two injectable GLP-1 agents used for weight management came from the STEP 8 randomised clinical trial, published in JAMA in 2022. The study enrolled adults with overweight or obesity without diabetes and compared once-weekly subcutaneous semaglutide 2.4 mg with once-daily liraglutide 3.0 mg over 68 weeks, and researchers reported a mean body-weight change of −15.8% with semaglutide versus −6.4% with liraglutide (PMID 35015037). Gastrointestinal adverse events were the most commonly reported category in both groups in that trial (PMID 35015037). A comparison of this kind describes relative magnitude; it does not alter either product's approved indication.

Adolescents

The adolescent extension of the indication covers ages 12 to 17 who meet the label's weight and BMI criteria. A 2025 review of GLP-1 receptor agonists and GIP/GLP-1 co-agonists examined obesity treatment specifically in adolescents and in older adults, noting that evidence in these groups developed later than the adult data (PMID 40716192). Decisions about adolescent treatment are made by a prescribing clinician against the current label and local guidance.

Uses that are not approved indications

The following appear in the published literature but are not part of the approved label. They are listed here so the boundary is explicit, not as suggestions.

Children under 12 years

A randomised trial published in the New England Journal of Medicine in 2025 evaluated liraglutide in children aged 6 to under 12 years with obesity, and researchers reported a greater reduction in BMI with liraglutide than with placebo alongside more frequent gastrointestinal adverse events (PMID 39258838). The study was a clinical trial in a population below the approved age range at the time it was published; trial results do not by themselves change a product label, and any regulatory extension is a separate process.

Inflammatory and immune-related conditions

A pharmacological review described anti-inflammatory and immunological properties of GLP-1 receptor agonists across experimental and clinical datasets (PMID 35738455). These are mechanistic and exploratory observations. No inflammatory or autoimmune indication appears on the Saxenda label.

Metabolic uses outside weight management

Glycaemic control in type 2 diabetes is an approved use of liraglutide under a different product and label, reviewed in the GLP-1 state-of-the-art summary (PMID 33068776). Prescribing one liraglutide product for the other product's indication is an off-label decision that belongs to a clinician, not to a summary page.

Adverse Events in Liraglutide Trials: What Studies Report

Safety information sits in the label's warnings and precautions sections and in the published literature. The STEP 8 trial reported gastrointestinal adverse events as the most frequent category among adults receiving daily liraglutide 3.0 mg or weekly semaglutide 2.4 mg over 68 weeks (PMID 35015037). The paediatric trial in children aged 6 to under 12 likewise reported that gastrointestinal adverse events occurred more often with liraglutide than with placebo (PMID 39258838).

A 2024 review written for emergency clinicians catalogued the acute presentations associated with GLP-1 receptor agonists, including nausea, vomiting, delayed gastric emptying, pancreatitis and hypoglycaemia when these agents are combined with insulin or sulfonylureas (PMID 38241775). The review of long-term anti-obesity treatment reported that tolerability and persistence on therapy were recurring limitations across approved agents (PMID 33410104). The label also carries class warnings — including a boxed warning regarding thyroid C-cell tumours observed in rodents — which a prescribing clinician reviews before treatment.

How to read the label-versus-literature distinction

1. Approved indication = what a regulator has reviewed and authorised, printed in the product's prescribing information.
2. Off-label use = a clinician prescribing an approved product outside that wording, a decision made case by case.
3. Investigational use = administration within a clinical trial, as in the trial of liraglutide in children aged 6 to under 12 (PMID 39258838).

Published efficacy data, however favourable, do not convert categories two or three into category one. Labels are also jurisdiction-specific and are updated over time, so the authoritative source for any given country is that country's current prescribing information.

Questions a prescribing clinician answers

• Whether an individual meets the label's BMI and comorbidity criteria described in pharmacotherapy reviews (PMID 39277293).
• How existing medications interact, including the hypoglycaemia risk flagged when GLP-1 agents are combined with insulin or sulfonylureas (PMID 38241775).
• What monitoring and follow-up look like over the long term, given the durability questions raised in reviews of anti-obesity treatment (PMID 33410104).
• Whether a daily or weekly agent fits a given clinical picture, in light of the comparative data reported in STEP 8 (PMID 35015037).

References

• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial (JAMA, 2022)
• GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art (Molecular Metabolism, 2021)
• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide (Journal of Medicinal Chemistry, 2015)
• The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
• Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial (New England Journal of Medicine, 2025)
• Management of obesity (Lancet, 2016)
• Weight Loss Pharmacotherapy: Current and Future Therapies (Gastrointestinal Endoscopy Clinics of North America, 2024)
• GLP-1 agonists: A review for emergency clinicians (American Journal of Emergency Medicine, 2024)
• The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists (Pharmacological Research, 2022)
• GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly (Medicina Clinica, 2025)
• Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions (Cell Metabolism, 2022)
• Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (Current Obesity Reports, 2021)